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Clinical Trials of Drug – Thalidomide, and Its Derivatives  Esaim Fadhel – Khalfa1       Alaa – Alaawad2 1.College of Pharmacy, University of Babylon, Hilla, Iraq 2.Oncology Center, Merjan Teaching Hospital, Hilla, iraq  Abstract In the clinic, I am following (114) patients suffering from Multiple Myeloma (MM), treated with a single dose capsule daily containing (50- 100 mg) of the drug. Thalidomide [1,2] has shown its efficacy in multiple myeloma [3,4], particularly in combination with cortisone. Currently it is used in combination with Melphalan and Prednisone (MPT) [5,6,7] as first-line therapy or in combination with Dexamethasone [8,9] (Dex-Tal) in relapsing patients. Bortezomib (Velcade®) is a very active drug in patients with multiple myeloma. It has been used in experimental protocols in various stages of the disease (first-line therapy or relapse). Many studies have shown a clear superiority of Bortezomib in combination with high-dose Dexamethasone or other drugs (Thalidomide, Doxorubicin, Cyclophosphamide), compared to conventional therapy.Recently Bortezomib (Velcade®) in association with Melphalan and Prednisone (VMP) has been approved as an alternative to the previous reference (MPT) scheme in patients not candidates for autologous transplantation [10,11,12]. Since it is not eliminated by the kidney it is the drug of first choice in patients with renal insufficiency. In pharmacokinetics profile in patients with multiple myeloma after oral administration of a single dose capsule containing (100mg) of the drug,HPLC – Technique is used for the determination of molecules [13]. Keywords: Multiple Myeloma (MM), Thalidomide, Lenalidomide Velcade®, Melphalan and Prednisone (MPT), HPLC-Technique.  1. Introduction Multiple myeloma (MM) - KAHLER – BOZZOLO disease It is a neoplasm supported by the proliferation of a neoplastic clone of plasma cell nature, cells belonging to the immune system present mainly in the bone marrow that have the function of producing antibodies. Molecular Pathogenesis Etiology 1- 2- 3- 4-Symptoms Therapy ... New therapies  1.1 Etiology The MM has basic oncogenic but its actual cause is not yet known. Surely ionizing radiation has a causal role, given its high incidence among the survivors of the atomic explosions and between radiologists exposed for a long time for professional reasons. A higher than average incidence was also reported among the farmers who have handled certain classes of pesticides or insecticides, industrial workers who handled based solvents benzene.  1.2 Molecular Pathogenesis Conventional cytogenetic analysis showed that in 30-59% of myeloma patients can be detected karyotypic abnormalities. The extent and frequency of these can be correlated with disease stage, prognosis and primary response to therapy. For example, it falls into average to find about 20% of abnormalities at I stage of the disease, which become 60% at the stage III and more than 80% when there are extra medullary disseminated metastases.  1.3 Symptoms Usually the symptoms are: • Bone pain; normally located along the spine, but can occur in any other way throughout the skeleton area. • Kidney failure • Hypercalcemia • Fatigue and general weakness • Neuropathy • Anaemia  1.4 Therapy New therapies include: • The use of Thalidomide and its derivatives, Lenalidomide, a derivative of thalidomide, is an immunomodulating agent, which interferes with the activity of the immune system. It blocks the development of tumour cells, inhibits angiogenesis (increase vessels of blood) and also stimulates 
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particular cells of the immune system to attack cancer cells. [14] Lenalidomide, compared to its progenitor molecule (thalidomide), is 50,000 times more effective in inhibiting TNF-α and has a lower incidence of side effects. [15] • The proteasome inhibitor Bortezomib, approved and given in combination with Melphalan • The ABT-737, an antagonist of Bc1-2 protein. It is also being studied in several types of cancers including brain tumours, kidney cancer, prostate cancer, colon carcinoma, pancreatic and breast and hepatocarcinoma.  2. Method In the clinic, I am following (114) patients suffering from MM, a relatively rare disease. They are of different sex (M, F), age, working classes. They are treated with a single dose capsule containing (50- 100 mg) of the drug. The incidence of myeloma increases with age. Most people with myeloma are more than 50 years old, only 10% of patients are under 40 years of age. The incidence has a percentage (1- 1.5 / 100,000). The male-female ratio is about 3-1 which means a greater incidence among males.  3. Strumentation The analysis was performed using a HPLC [16] Thermo Finingam SCM 1000 with Pump, detector VIS / UV and injector with loop of 20µl. The best conditions are as follows: • Analytical Column Hypersil BDS C18 (250 x 4.6 mm), preceded [17] from a pre-column, at a temperature of 20 ° C. • FM composed of 25% ACN and 75% 10mM ammonium acetate buffer pH 5.5. • Flow 1.5 ml / min. • UV detector, wavelength of 220 nm.  4. Materials and reagents • Thalidomide, Sigma aldrich® • phthalimide, Sigma aldrich® • Acetonitrile HPLC grade, Sigma aldrich® • Ammonium acetate, Carlo Erba.  5. Preparation mobile Phase A- For each half liter of solution weigh exactly 0.39 g of ammonium acetate (PM 77.08 g /mol) which are dissolved in 450 ml of bidistilled water. The pH is then 5.5 by the addition of acetic acid drop-drop. B- Acetonitrile.  6. Calibration line of Thalidomide The intermediate standard was then injected in order to determine the area.  As the solution 0.05µg/ml was not quantifiable, the curve was built on 6 points. Concentration (µg/ml):          Medium area           A1              A2                       A3            0,1                                                 13509                  13299          13512          13706 0,4                                                 56932                  56915          56910          56971 0,8                                              112456                 112488         112407        112473 2,0                                              290656                 290595         290597        290776 4,0                                              611854                 611931         611660        611971 5,0                                              766438                 766429         766435        766450 Table 1.   Preparations of the dilutions and the calibration curves of the Phthalimide The intermediate standards were prepared and injected into as for Thalidomide.  The results obtained are reported in Table 2. Concentration (µg/ml):        Medium area                  A1                    A2                     A3       0,1                                               23398                      23450            23345            23399 0,4                                               86542                      86562            86520            86544 0,8                                              178975                     178953           178997         178975 2,0                                              452827                     452923           452726          452832 4,0                                             901234                      901280           901984          901032 5,0                                           1127849                   1127853         1127912         1127782 Table 2. 
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